RedShift BioAnalytics releases biomolecule characterization technology

By The Science Advisory Board staff writers

May 4, 2022 -- RedShift BioAnalytics has launched its novel Apollo technology for advanced microfluidic modulation spectroscopy (MMS). This technology enables highly sensitive and precise measurement of biomolecules with improved efficiency and decreased sample volume compared to the company's previous AQS3 pro structural analysis technology.

Through the use of its updated software and analytics capabilities, Apollo characterizes the structural attributes of biomolecules in a reproducible manner with a broad concentration range from 0.1 mg/mL to greater than 200 mg/mL. Additionally, the technology reduces background noise and interference of excipients using real-time buffer subtraction. Through these features, Apollo supports the analysis and structural comparisons between various molecules, including viral vectors, mRNA, and antibody drug conjugates. This provides great utility in the discovery, screening, formulation, and quality control processes during drug development.

Apollo MMS technology. Photo courtesy of Business Wire.
Sciex to resell RedShiftBio's new technology
Sciex has inked a deal to resell the AQSPro from RedShift Bioanalytics (RedShiftBio) throughout the U.S., providing more biopharmaceutical labs with access...
RedShift Bioanalytics nets $20M in new financing
RedShift BioAnalytics has finalized a $20 million series E funding round. The firm is developing platform technology to enable the measurement of...

Copyright © 2022

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter